FI82073B - Framstaellningsfoerfarande foer epidermin, en antibiotisk polypeptid. - Google Patents

Framstaellningsfoerfarande foer epidermin, en antibiotisk polypeptid. Download PDF

Info

Publication number
FI82073B
FI82073B FI854316A FI854316A FI82073B FI 82073 B FI82073 B FI 82073B FI 854316 A FI854316 A FI 854316A FI 854316 A FI854316 A FI 854316A FI 82073 B FI82073 B FI 82073B
Authority
FI
Finland
Prior art keywords
epidermin
acid
extract
acetic acid
ala
Prior art date
Application number
FI854316A
Other languages
English (en)
Finnish (fi)
Other versions
FI854316A (fi
FI854316A0 (fi
FI82073C (sv
Inventor
Guenther Jung
Rolf-Guenther Werner
Hans Zaehner
Hermann Allgaier
Ursula Schneider
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19843440423 external-priority patent/DE3440423A1/de
Priority claimed from DE19853523478 external-priority patent/DE3523478A1/de
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of FI854316A0 publication Critical patent/FI854316A0/fi
Publication of FI854316A publication Critical patent/FI854316A/fi
Application granted granted Critical
Publication of FI82073B publication Critical patent/FI82073B/fi
Publication of FI82073C publication Critical patent/FI82073C/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/44—Staphylococcus
    • C12R2001/45—Staphylococcus epidermidis

Claims (2)

1. Karaktär: färglöst pulver;
2. Löslighet: löser sig synnerligen väl i vatten/isättika- eller metanol/isättika-blandningen, löser sig i lägre alkoholer, olöslig i kloroform, aceton, dietyleter, petroleter;
3. Färgreaktioner p& silicagelskivor: ninhydrin, klor/TDM (TDM = 4,4'-bis-(dimety1amino)difenyImetän), orsin/svave1_ syra, anisa1dehyd/svave1syra. Färdiga si1ikage1 skivor
60 F254 (Merck). System A: k 1oroform/metano1/17¾ ammoniak (2/2/1) RF = 0,73 System B: kloroform/metano/17% ammoniak (70/35/10) RF = 0,30 System C: n-butanol/isättika/vatten (4/1/1) RF = 0,05
5. HPLC: se figur 7;
6. Stabilitet: stabil i pH-omr&det 2-7, vid högre pH-värden sker kraftig effektivitetsnedg&ng;
7. Molmassa: ca. 2160 (utan anjoner);
8. Uitraviolettabsorptionsspektrum: i vattenlösning längv&gs-maximum 267 nm (figur 3);
9. InfraröttabsorptIonsspektrum: IR-spektrum i ett prov i kaiiumbromidtabletter (figur 4);
10. Kärnmagnetiskä resonansspektra 1H-NMR spektrum: figur 5, 13C-NMR-spektrum: figur 6, kännetecknat därav, att Staphylococcus epidermidis DSM 3095 stammen odlas aeroboiskt vid 34 - 37°C i rik närings-lösning, som inneh&ller 2 - 4 % köttextrakt, 1 - 3 % socker eller sockeralkohol, som best&r av maltextrakt och/eller maltos, och därtill eventuallt laktos och/eller galaktos och/eller glukos och/eller mannit och/eller glyserin, och 0,25 - 1 % kalciumkarbonat eller 0,25 - 0,5 H kalciumhydroxid, after avl&gsnande av celler och oorganiska salter antingen extraheras odlingslösningen efter isolering av bildat effektiv-ämne med n-butanol vid ett pH-värdet av 8, butano1extraktet indunstas, Äterstoden upplöses i metanol och fr&n lösningen 42 82073 avlägsnas medföljanade lipidämnen genom eterutfälIning eller behandlas med akrylester- eller polystyrenbaserade polymerer, varvid det absorberade epiderminet utlöses hartsen metanol/-koncentrerad saltsyra (99:1), varefter lösningen neutraliseras med ammoniak och indunstans i vakuum, och fr&n det sk erh&llna isolationsmaterialet avskiljes övriga 1&gmo1eky1ära peptider, aminosyror och salter genom ge1kromatografi (med Sephadex LH-20 metanol/ättiksyra (95:5)) och därefter utföres en duplicerbar motsrömsextraktion enligt Craig genom att först utföra en vätske-vätske-extraktion med n-butanol/ättiksyraester/O,1 N ättiksyra (3:1:3) system, där epiderminet vid starten sitter kvar och därefter isoleras epiderminet i en andra extraktion med ett neutralt 2-butanol/0,05 N ammoniumasetat (1:1) system, och epidermin isoleras frän eluatet som ett färglöst pulver genom frystorkning.
1. Förfarande för framstälIning av en antibiotiskt effektiv epidermin benämnd polypeptid med följande aminosyrasamman-sättning: Arn (1), Pro (1), Gly (2), Ala (2), Ile (2), Phe (2), Lys (2), Lan (2), Ö-Me-Lan (1), Dhb (1), Tyr (1), S-(2-amino-vinyl)-D-cystein (1) och följande primärkonstruktion: meso-1antionin CH2 - S --CHz I I H-l1e-A1a-NH-CH-CO-Lys-Phe-Ile-NH-CH-CO-- (S) (E) CH3 β-mety Hantionin (S)CH - S - CH2 Ίι I — NH-CH-CO-Pro-G1y-NH-CH-CO-A1a-Lys-. (S) (E) CHa meso-1antionin CH CH2 - S---— CH2 (S) (Z) _ NH-C-CO-G1y-HN-CH-CO-Phe-Asn-HN-CH-CO-Tyr-HN-CH-CO-NH-CH (Z) (S) | (E) Il CH2 - s - CH S-(2-aminoviny1)-D-kystein varvid de enskilda tioeteraminosyrornas närä N-terminalen belägna hälfter i respektive fall har en D-konfiguration, och följande andra parametrar: 41 82073
2. Förfarande enligt patentkravet 1, kännetecknat därav, att som fermenterinsmediets kvävekälla används 2-4 viktprocent köttextrakt eller en blandning av alla 20 aminosyror respektive i en aminosyrakoncentration av 2 g/1 eller 2 - 4 % Cas-aminosyra i närvaro av tryptofan coh vitaminer, s&som biotin, nikotinsyra, tiamin, pyroxinhydroklorid och kalciumpantotenat, som kolkällor 1-3 viktprocent malt-extrakt eller maltos, eventuellt med tillsats av laktos och/eller galaktos och/eller mannit och/eller glukos och/eller glyserin, 0,25 - 1 viktprocent kaiciumkarbonat eller 0,25 - 0,5 viktprocent kalsiumhydroxid fermenteringens pH-värde regleras tili 6,0 - 7,0 och utbytesförloppet följes genom kontinuerlig provtagning. Il
FI854316A 1984-11-06 1985-11-04 Framställningsförfarande för epidermin, en anbiotisk polypeptid FI82073C (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE3440423 1984-11-06
DE19843440423 DE3440423A1 (de) 1984-11-06 1984-11-06 Antibiotisches polypeptid, verfahren zu seiner herstellung, dieses polypeptid erzeugender stamm von staphylococcus epidermidis, dieses polypeptid enthaltende zubereitungsformen und seine verwendung zur bekaempfung infektioeser erkrankungen
DE19853523478 DE3523478A1 (de) 1985-07-01 1985-07-01 Antibiotisches polypeptid, verfahren zu seiner herstellung, dieses polypeptid erzeugender stamm vom staphylococcus epidermidis, dieses polypeptid enthaltende zubereitungsformen und seine verwendung zur bekaempfung infektioeser erkrankungen
DE3523478 1985-07-01

Publications (4)

Publication Number Publication Date
FI854316A0 FI854316A0 (fi) 1985-11-04
FI854316A FI854316A (fi) 1986-05-07
FI82073B true FI82073B (fi) 1990-09-28
FI82073C FI82073C (sv) 1991-01-10

Family

ID=25826263

Family Applications (1)

Application Number Title Priority Date Filing Date
FI854316A FI82073C (sv) 1984-11-06 1985-11-04 Framställningsförfarande för epidermin, en anbiotisk polypeptid

Country Status (13)

Country Link
EP (1) EP0181578B1 (sv)
JP (2) JPH0670078B2 (sv)
KR (1) KR930002736B1 (sv)
CA (1) CA1277617C (sv)
DE (1) DE3583987D1 (sv)
DK (1) DK172818B1 (sv)
ES (1) ES8702924A1 (sv)
FI (1) FI82073C (sv)
HK (1) HK63795A (sv)
IL (1) IL76956A (sv)
NO (1) NO164039C (sv)
NZ (1) NZ214067A (sv)
PT (1) PT81436B (sv)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0637384B2 (ja) * 1985-09-21 1994-05-18 株式会社資生堂 皮膚化粧料
EP0350810B1 (de) * 1988-07-15 1993-09-29 Dr. Karl Thomae GmbH Verfahren zur Gewinnung, Isolierung und Reinigung von Epidermin
DE3938140A1 (de) * 1989-11-16 1991-08-08 Beiersdorf Ag Desodorierende kosmetische mittel
AU5158093A (en) * 1992-09-10 1994-03-29 Sara Lee/De N.V. Mouth-care products with anti-bacterial activity
NZ271650A (en) * 1993-08-20 1997-11-24 Novartis Ag New use for gallidermin and epidermin
EP0759077A1 (en) * 1994-05-07 1997-02-26 Ciba-Geigy Ag Lanthionine-containing antimicrobial compound
WO1996031192A1 (de) * 1995-04-07 1996-10-10 Kuyus-Stiftung Kosmetische zusammensetzung zur behandlung von cellulite
SE9602496D0 (sv) 1996-06-20 1996-06-20 Bengt Guss Method and means for producing a fibrinogen binding protein and its use in biotechnology
JP2006176406A (ja) * 2003-03-11 2006-07-06 Asahi Kasei Pharma Kk ペプチド系抗生物質
KR20230078378A (ko) * 2021-11-26 2023-06-02 코스맥스 주식회사 에피더미디박테리움 케라티니 추출물이 함침된 다공성 실리카 및 그의 피부상태 개선 용도

Also Published As

Publication number Publication date
JPS61158997A (ja) 1986-07-18
DK509985A (da) 1986-05-07
EP0181578B1 (de) 1991-09-04
EP0181578A3 (en) 1988-08-17
DK509985D0 (da) 1985-11-05
ES8702924A1 (es) 1987-01-16
EP0181578A2 (de) 1986-05-21
PT81436B (pt) 1988-01-22
FI854316A (fi) 1986-05-07
DE3583987D1 (de) 1991-10-10
FI854316A0 (fi) 1985-11-04
NO854405L (no) 1986-05-07
PT81436A (de) 1985-12-01
NO164039B (no) 1990-05-14
KR860004147A (ko) 1986-06-18
NO164039C (no) 1990-08-22
JPH0732704B2 (ja) 1995-04-12
DK172818B1 (da) 1999-08-02
IL76956A (en) 1991-07-18
NZ214067A (en) 1991-05-28
HK63795A (en) 1995-05-05
JPH06113826A (ja) 1994-04-26
FI82073C (sv) 1991-01-10
IL76956A0 (en) 1986-04-29
JPH0670078B2 (ja) 1994-09-07
CA1277617C (en) 1990-12-11
KR930002736B1 (ko) 1993-04-09
ES548544A0 (es) 1987-01-16

Similar Documents

Publication Publication Date Title
EP0342486B1 (en) Antibiotic
CA2295986C (en) Novel antimicrobial polypeptide and methods of use
JPH0637508B2 (ja) 抗生物質Ａ４０９２６複合体およびその純粋な因子ＰＡ、ＰＢ、Ａ、ＢおよびＢｏ
FI82073B (fi) Framstaellningsfoerfarande foer epidermin, en antibiotisk polypeptid.
EA016608B1 (ru) Антибиотик 107891, его фармацевтически приемлемые соли, фармацевтическая композиция и применение
HU188684B (en) Process for producing a2, and simultaneously produced a1 and a3 components of antibioticum a/16686
KR20110014563A (ko) 악티노마두라 나미비엔시스로부터 유래된 고도로 브릿징된 펩타이드
EP0668358B1 (en) Antibiotic WAP-8294A, method for preparing the same and antibacterial composition
US6964760B2 (en) Antimicrobial polypeptide, nucleic acid, and methods of use
AU596082B2 (en) Antibiotic polypeptide
EP0675900B1 (en) Antibiotics ge 37468 a, b and c
US7067125B2 (en) Antimicrobial polypeptides and methods of use
US4513083A (en) Preparation of an antibiotic selectively effective against staphylococcus infections
FI73738C (sv) Förfarande för framställning av ett stafylocidinantibiotikum, vilket ä r bundet till cellmureinet och har en selektiv antimikrobiell aktivite t mot stafylokocker.
DE3523478A1 (de) Antibiotisches polypeptid, verfahren zu seiner herstellung, dieses polypeptid erzeugender stamm vom staphylococcus epidermidis, dieses polypeptid enthaltende zubereitungsformen und seine verwendung zur bekaempfung infektioeser erkrankungen
EA012164B1 (ru) Антибиотик 107891, его факторы а1 и а2, фармацевтически приемлемые соли и композиции и их применение
DK175198B1 (da) Antibioticum, betegnet gallidermin, og syreadditionssalte deraf, farmaceutiske og kosmetiske præparater indeholdende forbindelserne og fremgangsmåde til forbindelsernes fremstilling samt deres anvendelse til fremstilling af et farmaceutisk præparat
EP1481986A1 (en) Antibiotic 97518, pharmaceutically acceptable salts and compositions, and use thereof
NO822016L (no) Nye antibiotisk virksomme forbindelser, fremgangsmaate til deres fremstilling samt deres anvendelse som legemidler
US20060198793A1 (en) Antimicrobial polypeptide, nucleic acid, and methods of use
IE913058A1 (en) Antibiotic ge1655 complex and its factors a, b, and c
JPH05255389A (ja) サイクロペプチド化合物
JPS60239424A (ja) 抗腫瘍性物質ｓｐｆ―１０００及びその製法
JPH0156078B2 (sv)
WO2012062906A1 (en) Peptides as bioactive compounds

Legal Events

Date Code Title Description
FG Patent granted

Owner name: DR. KARL THOMAE GESELLSCHAFT MIT

MA Patent expired